Cefaclor is a second generation cephalosporin antibiotic which has stability against b-lactamase inactivation and possesses a broad spectrum of activity. Cefaclor is active against the following organisms in vitro: Alpha and beta haemolytic Streptococci, Staphylococci; including coagulase-positive, coagulase negative and penicillinase-producing strains, Streptococcus pneumoniae, Streptococcus pyogenes (Group A b-haemolytic Streptococci), Branhamella catarrhalis, Escherichia coli, Proteus mirabilis, Klebsiella species Haemophilus influenzae, including ampicillin-resistant strains. Cefaclor is generally effective in the eradication of Streptococci from the nasopharynx.
Loracef powder of suspension
Usual dose: 250 mg 8 hrly.
Bronchitis & pneumonia: 250 mg tid.
Sinusitis: 500 mg tid for 10 days.
Pneumonia & other more severe infections: Max: 4 gm/day for 28 days.
Acute gonococcal urethritis: 3 gm as a single dose combined with probenecid 1 gm.
Recommended dose: 20 mg/kg/day in divided doses 8 hrly.
Bronchitis & pneumonia: 20 mg/kg/day in divided doses tid.
Serious infections, sinusitis, otitis media & infections: caused by less susceptible organisms 40 mg/kg/day in divided doses. Max: 1 gm/day.